Back to Publications

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

Download all
TitleDescriptionDownload
Semaglutide Use Among Individuals Diagnosed with Metabolic-dysfunction Associated Steatotic Liver Disease in a Medicare Advantage Program

Poster Presentation

DownloadPreview
Semaglutide Titration Patterns Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Poster Presentation

DownloadPreview
Semaglutide Discontinuation Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Poster Presentation

DownloadPreview
Role of metabolic dysfunction-associated steatohepatitis (MASH) as a risk factor for hepatocellular carcinoma (HCC) development

Poster Presentation

DownloadPreview
Patient characteristics and treatment patterns among patients using resmetirom in the real-world setting

Poster Presentation

DownloadPreview
Evaluating the early real-world impact of resmetirom in patients with metabolic dysfunction-associated steatohepatitis (MASH): A United States cohort study using electronic medical records

Poster Presentation

DownloadPreview
Characterizing Healthcare Costs in Medicare Beneficiaries with a New Diagnosis of Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis

Poster Presentation

DownloadPreview
Characterizing Healthcare Costs in Medicare Beneficiaries with a New Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensated Cirrhosis

Poster Presentation

DownloadPreview
An Innovative Screening and Treatment Pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease: The UK-CURES Approach

Poster Presentation

DownloadPreview